US · Healthcare · Biotechnology
EPS came in at -1.99 against a street estimate of -2.55 — a beat of 22.0%.
Analysts rate Madrigal Pharmaceuticals Inc a buy (13 buy, 1 hold, 1 sell out of 15) with an average price target of $682.93.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 9.27% |
| HHG PLC | 8.74% |
| RTW INVESTMENTS, LLC | 8.63% |
| venBio Select Advisor LLC | 7.87% |
| BlackRock Inc | 6.75% |
| Paulson & Company Inc | 6.03% |
| Vanguard Portfolio Management, LLC | 3.64% |
| Vanguard Capital Management, LLC | 3.58% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-30 |
| Board / officer change · Q2 2026 | 2026-06-17 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-06 |
| Board / officer change · Q2 2026 | 2026-04-28 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Annual report FY2025 | 2026-02-19 |
Readable in the app.
| Announcement | Date |
|---|---|
| Enters material definitive agreement with Roche Madrigal Pharmaceuticals announced on January 29, 2026 that it has amended its long-standing commercialization agreement with Roche (dating back to 2008) regarding Rezdiffra, the company's d | 2026-01-30 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Madrigal Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.